reference/24431732

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24431732

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	1668
issn	0028-4793 1533-4406
issueIdentifier	18
pageRange	1656-1668
publicationName	The New England journal of medicine
startingPage	1656
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a5a3cb2593dfab09c6742fd1e4c037f7 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_26fba9456e1e33d5671ff7055ed23621
bibliographicCitation	Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, Maspero JF, Abdulai RM, Hu CC, Martincova R, Jessel A, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656–68. doi: 10.1056/nejmoa2024257. PMID: 34706171.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2baf580512b3fd4fcaf22232a52f09b9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_62ccf9449f03e727e566ffc71d464533 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e3109afe241e0fe8626fd8031703d7bb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_489fbde92974b9a0b7480958897d09a7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7f7707c2329abaf4f4812f022b005e9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a9bb1a7502d760abc550633d445fff4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bda328c88906ee26a3b062daaa2984b7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3063ffce4e475b954d56e886961f9597 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1188528d48e53ce7b8f24bea01d1f5df http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6bf0548bdfe2755a5c8c5ab8b5eeae3d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_41234b614f6e42df3ae0b0c7b69d22ff http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2019978a3d7009e7fc98831ac155222f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d62ec755f2bde64145bd9b8dbfdd458 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_07b10dcc0a2f16c7313f03f2f79425ed http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_453010bd198651c10f670abc69f7de10 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b60fbdb623085bb70276a2e36e900b1d
date	2021-10-28^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1056/nejmoa2024257 https://pubmed.ncbi.nlm.nih.gov/34706171
isPartOf	https://portal.issn.org/resource/ISSN/1533-4406 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5985 https://portal.issn.org/resource/ISSN/0028-4793
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
discusses	http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0028296 http://id.nlm.nih.gov/mesh/M0586196 http://id.nlm.nih.gov/mesh/M000600385 http://id.nlm.nih.gov/mesh/M0029620 http://id.nlm.nih.gov/mesh/M0009322
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D061067Q000627 http://id.nlm.nih.gov/mesh/D018927Q000627 http://id.nlm.nih.gov/mesh/D000067596Q000037
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D019948Q000037 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D005938Q000627 http://id.nlm.nih.gov/mesh/D001249Q000188 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D007279 http://id.nlm.nih.gov/mesh/D011788 http://id.nlm.nih.gov/mesh/D004359 http://id.nlm.nih.gov/mesh/D017211 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D018927Q000009 http://id.nlm.nih.gov/mesh/D000368
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_69c8365c5e015aa60518d03ac8157056 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f86d012b6bfa338654b1bd0723e283bf http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fee377b7382874724b5dd6d1ce1612cc http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6985 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_5282077eb6f2e0ad7e7bc4da2627c39c

Showing number of triples: 1 to 66 of 66.